EHA 2019 | Venetoclax plus obinutuzumab in CKT CLL: analysis from the CLL14 trial

Othman Al-Sawaf

Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, talks about venetoclax plus obinutuzumab in CKT CLL. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video